Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease
Intestinal Research · 07.05.2026
DOI: 10.5217/ir.2025.00232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 07.05.2026. Verfasst von Gursimran S Kochhar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
- Department of Medicine, Allegheny Health Network, Pittsburgh, PA, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Northwestern University, Chicago, IL, USA.
Zitieren
APA
Kochhar, G. S., Khataniar, H., Dulai, P. S., & Desai, A. (2026). Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease. Intestinal Research. https://doi.org/10.5217/ir.2025.00232
Vancouver
Kochhar GS, Khataniar H, Dulai PS, Desai A. Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease. Intestinal Research. 2026. doi:10.5217/ir.2025.00232
BibTeX
@article{Kochhar2026,
author = {Kochhar, Gursimran S and Khataniar, Himsikhar and Dulai, Parambir S and Desai, Aakash},
title = {Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease},
journal = {Intestinal Research},
year = {2026},
doi = {10.5217/ir.2025.00232}
}
EUVIMED